Overview

A Study Using Micronised Progesterone (Crinone® 8%) in the Luteal Phase Support of Women Undergoing in Vitro Fertilisation (IVF) and Embryo Transfer (ET)

Status:
Completed

Trial end date:
2005-05-01

Target enrollment:

Participant gender:

Summary

This was an open-label, randomized, comparative, phase III study to evaluate the safety and efficacy of Crinone 8% in comparison with progesterone 60 mg intramuscular (i.m.) administered once a day in luteal phase support in 200 Chinese female subjects undergoing IVF/ET.

Phase:

Phase 3

Details

Lead Sponsor:

Merck KGaA
Merck KGaA, Darmstadt, Germany

Treatments:

Progesterone